Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Total Current Liabilities over the past 11 years, most recently at $384.0 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 11.63% to $384.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $384.0 million through Dec 2025, up 11.63% year-over-year, with the annual reading at $384.0 million for FY2025, 11.63% up from the prior year.
  • Total Current Liabilities was $384.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $340.0 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $384.0 million in Q4 2025 and troughed at $127.0 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $249.8 million (2023), against an average of $245.1 million.
  • Year-over-year, Total Current Liabilities crashed 35.46% in 2021 and then surged 73.64% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $181.4 million in 2021, then surged by 44.02% to $261.2 million in 2022, then grew by 7.36% to $280.4 million in 2023, then grew by 22.67% to $344.0 million in 2024, then increased by 11.63% to $384.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Total Current Liabilities are $384.0 million (Q4 2025), $340.0 million (Q3 2025), and $293.2 million (Q2 2025).